- Home
- EEA vs CCEL Comparison
EEA vs CCEL Comparison
Compare EEA & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEA
- CCEL
- Stock Information
- Founded
- EEA 1986
- CCEL 1989
- Country
- EEA Germany
- CCEL United States
- Employees
- EEA N/A
- CCEL N/A
- Industry
- EEA Trusts Except Educational Religious and Charitable
- CCEL Managed Health Care
- Sector
- EEA Finance
- CCEL Health Care
- Exchange
- EEA Nasdaq
- CCEL Nasdaq
- Market Cap
- EEA 60.8M
- CCEL 50.0M
- IPO Year
- EEA N/A
- CCEL 1997
- Fundamental
- Price
- EEA $8.39
- CCEL $7.40
- Analyst Decision
- EEA
- CCEL
- Analyst Count
- EEA 0
- CCEL 0
- Target Price
- EEA N/A
- CCEL N/A
- AVG Volume (30 Days)
- EEA 9.2K
- CCEL 13.7K
- Earning Date
- EEA 01-01-0001
- CCEL 02-26-2025
- Dividend Yield
- EEA 1.92%
- CCEL 3.38%
- EPS Growth
- EEA N/A
- CCEL N/A
- EPS
- EEA N/A
- CCEL N/A
- Revenue
- EEA N/A
- CCEL $31,838,476.00
- Revenue This Year
- EEA N/A
- CCEL $3.97
- Revenue Next Year
- EEA N/A
- CCEL $0.91
- P/E Ratio
- EEA N/A
- CCEL N/A
- Revenue Growth
- EEA N/A
- CCEL 1.95
- 52 Week Low
- EEA $7.45
- CCEL $4.47
- 52 Week High
- EEA $9.26
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- EEA 52.53
- CCEL 46.30
- Support Level
- EEA $8.05
- CCEL $6.74
- Resistance Level
- EEA $8.27
- CCEL $7.50
- Average True Range (ATR)
- EEA 0.10
- CCEL 0.42
- MACD
- EEA 0.02
- CCEL -0.02
- Stochastic Oscillator
- EEA 92.27
- CCEL 56.42
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.